OPEN ACCESS

Middle East Research Journal of Nursing
ISSN 2789-8679 (Print) & ISSN: 2958-2016 (Online)
Frequency: Bi-Monthly
DOI: https://doi.org/10.36348/merjn.2024.v04i05.001

KUWAIT SCHOLARS PUBLISHER
Website: http://www.kspublisher.com/
Email: office@kspublisher.com

An Insight into Red Cell Distribution Width Fluctuations and Pregnancy Outcomes in HIV-Affected Women

Emmanuel Ifeanyi Obeagu[1*]
[1]Department of Medical Laboratory Science, Kampala International University, Uganda

Abstract: Red Cell Distribution Width (RDW), a measure of the variability in red blood cell size, has gained attention as a potential biomarker for assessing pregnancy outcomes, particularly in women living with HIV. This review explores the relationship between RDW fluctuations and maternal and fetal health during pregnancy in HIV-affected women. Elevated RDW levels have been associated with various adverse outcomes, including preeclampsia, preterm birth, and low birth weight, which are of significant concern in this population. HIV infection introduces additional complexity to pregnancy, increasing the risk of complications for both mother and infant. The interaction between HIV, antiretroviral therapy, and RDW levels can influence maternal hematological health, potentially affecting pregnancy outcomes. This review examines current literature to understand how RDW variations correlate with these complications and the implications for maternal and fetal well-being.

Keywords: Red Cell Distribution Width, Pregnancy Outcomes, HIV, Maternal Health, Fetal Health.

Review Paper

***Corresponding Author:**
Emmanuel Ifeanyi Obeagu
Department of Medical Laboratory Science, Kampala International University, Uganda

How to cite this paper:
Emmanuel Ifeanyi Obeagu (2024). An Insight into Red Cell Distribution Width Fluctuations and Pregnancy Outcomes in HIV-Affected Women. *Middle East Res J Nursing*, *4*(5): 61-65.

Article History:
| Submit: 12.08.2024 |
| Accepted: 10.09.2024 |
| Published: 12.09.2024 |

INTRODUCTION

Pregnancy in women living with HIV presents unique challenges, often resulting in an increased risk of adverse outcomes for both the mother and the infant [1]. One aspect of maternal health that has garnered attention in recent years is Red Cell Distribution Width (RDW), a hematological parameter reflecting the variability in red blood cell size. RDW is derived from standard complete blood count (CBC) tests and is calculated as the coefficient of variation of red blood cell volume. Elevated RDW levels can indicate increased anisocytosis, which may be associated with various health conditions, including anemia and inflammation. This review aims to explore the relationship between RDW fluctuations and pregnancy outcomes in HIV-affected women, highlighting its potential as a biomarker for monitoring and managing complications during pregnancy [2-6]. During pregnancy, the physiological changes in the maternal body, including hemodilution and alterations in red blood cell production, can cause fluctuations in RDW [7]. Typically, RDW levels increase in response to anemia, which is common in pregnant women due to the increased demand for red blood cells. However, elevated RDW levels have also been linked to complications such as preeclampsia, gestational diabetes, and preterm birth [8]. HIV infection introduces additional complexity to pregnancy by increasing the likelihood of adverse maternal and fetal outcomes. Women living with HIV face a higher risk of preterm birth, low birth weight, and vertical transmission of the virus. The interplay between HIV, antiretroviral therapy (ART), and RDW levels is of particular interest, as HIV and its treatment can affect various hematological parameters, including RDW. Evaluating how RDW changes in this context may offer valuable information for managing pregnancy and improving outcomes [9-11].

The role of RDW in pregnancy has been studied extensively in non-HIV populations, where elevated RDW levels have been associated with several adverse outcomes. For instance, high RDW has been linked to preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage. Similarly, elevated RDW levels have been associated with an increased risk of gestational diabetes and preterm delivery. Given the unique challenges faced by HIV-affected women, investigating whether RDW holds the same predictive value in this population is crucial [12, 13]. Studies have shown variable results regarding the association between RDW and pregnancy outcomes in HIV-positive women. Some research suggests a significant correlation between high RDW levels and adverse outcomes, while other studies find weaker associations. These discrepancies underscore the need

for further investigation to establish RDW's role as a reliable biomarker for monitoring pregnancy in HIV-affected women. Comprehensive analysis of existing studies can help clarify these associations and guide future research [15, 16]. Moreover, integrating RDW measurements into routine prenatal care for HIV-positive women could enhance monitoring and management of potential complications [16]. Regular assessment of RDW may aid in the early detection of issues such as anemia or inflammation, which could be indicative of more severe complications. Implementing such monitoring strategies could improve pregnancy care and outcomes for this vulnerable population.

RDW and Its Clinical Significance

Red Cell Distribution Width (RDW) is a hematological parameter that quantifies the variability in the size of red blood cells (RBCs). It is derived from the complete blood count (CBC) and is expressed as a percentage, representing the coefficient of variation of red blood cell volume. RDW is measured using automated hematology analyzers that calculate the width of the histogram of red blood cell sizes. Typically, RDW values are reported as RDW-CV (coefficient of variation) and RDW-SD (standard deviation), with RDW-CV being more commonly used [17]. Normal RDW-CV values generally range between 11.5% and 14.5%, although these ranges can vary slightly depending on the laboratory and population studied. Under normal circumstances, RDW reflects a narrow range of RBC sizes due to the uniform nature of healthy red blood cells [18]. However, various conditions can cause increased RDW levels, indicating greater variability in cell size, known as anisocytosis. Elevated RDW is commonly associated with different types of anemia, including iron-deficiency anemia, vitamin B12 deficiency anemia, and folate deficiency anemia. Additionally, increased RDW levels can occur in inflammatory and chronic disease states, such as chronic kidney disease and cardiovascular diseases, where the body's response to these conditions affects red blood cell production and turnover.

RDW serves as a valuable diagnostic tool due to its ability to provide insights into underlying health conditions beyond the presence of anemia [19]. High RDW levels can signal the presence of various disorders and can aid in differentiating between different types of anemia. For instance, in iron-deficiency anemia, RDW is often elevated alongside low mean corpuscular volume (MCV), whereas in anemia of chronic disease, RDW may remain normal or only slightly increased. Additionally, RDW has been implicated in the prognosis of several diseases. Elevated RDW levels have been linked to poor outcomes in cardiovascular diseases, such as heart failure and myocardial infarction, highlighting its potential as a prognostic marker. In pregnant women, RDW levels can fluctuate due to physiological changes such as hemodilution and increased red blood cell production [20]. While some variability in RDW is normal, significant deviations from the typical range can indicate underlying problems. For example, elevated RDW in pregnant women has been associated with adverse pregnancy outcomes, including preeclampsia, gestational diabetes, and preterm birth. This makes RDW a useful parameter for monitoring pregnant women, particularly those at risk for complications. By assessing RDW levels, clinicians can gain insights into the potential development of these conditions and take appropriate actions to manage and mitigate risks.

In the context of HIV infection, RDW can be influenced by both the virus itself and the effects of antiretroviral therapy (ART). HIV can cause chronic inflammation and affect red blood cell production, leading to alterations in RDW levels. ART can also impact hematological parameters, including RDW, through its effects on bone marrow function and overall health. Understanding how RDW behaves in HIV-positive individuals can provide valuable information for managing the health of these patients, particularly during pregnancy when the risk of complications is heightened [21-23]. Given its role in reflecting variability in red blood cell size and its associations with various health conditions, RDW holds potential as a biomarker for monitoring and predicting health outcomes. In the context of pregnancy, especially in HIV-positive women, RDW could serve as an early indicator of potential complications, aiding in the timely intervention and management of adverse events [24].

RDW in Pregnancy

During pregnancy, several physiological changes occur that can influence Red Cell Distribution Width (RDW) [25]. These changes include hemodilution, increased plasma volume, and altered red blood cell production, which can cause fluctuations in RDW levels. Hemodilution, a common phenomenon during pregnancy, results from the expansion of plasma volume relative to red blood cell mass, often leading to a slight decrease in RDW. However, RDW can also increase due to the body's increased demand for red blood cells and the possible presence of nutritional deficiencies or other underlying conditions. Elevated RDW levels during pregnancy have been linked to a range of complications [26]. High RDW is associated with conditions such as preeclampsia, gestational diabetes, and preterm birth. Preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ dysfunction, has been associated with increased RDW levels, suggesting that RDW might serve as an early marker for this condition. Similarly, elevated RDW has been found to correlate with an increased risk of gestational diabetes, potentially reflecting underlying inflammation or metabolic disturbances. Preterm birth, another adverse outcome associated with elevated RDW, may be influenced by the interplay between RDW and other maternal factors.

The mechanisms through which RDW levels fluctuate during pregnancy are multifaceted [27]. RDW can be influenced by changes in red blood cell production and turnover, which are altered in response to pregnancy-related demands. Nutritional deficiencies, such as iron, folate, or vitamin B12 deficiencies, can also impact RDW. These deficiencies may lead to increased RDW due to the production of abnormally sized red blood cells. Additionally, chronic inflammation or infections during pregnancy can affect RDW levels, contributing to variations in its measurement. Monitoring RDW during pregnancy can provide valuable insights into maternal health and potential complications [28]. Elevated RDW levels may indicate an increased risk of adverse outcomes and prompt further investigation or intervention. For instance, in women with high RDW, additional assessments for anemia, nutritional deficiencies, or inflammatory conditions might be warranted. Integrating RDW measurements into routine prenatal care can enhance the ability to detect and manage complications early, potentially improving maternal and fetal outcomes. In HIV-affected pregnancies, RDW can serve as an additional marker of concern due to the complex interactions between HIV, antiretroviral therapy (ART), and hematological parameters. HIV infection can lead to chronic inflammation and alterations in red blood cell production, which may affect RDW levels. ART, while essential for managing HIV, can also influence RDW through its effects on bone marrow and overall health. Monitoring RDW in HIV-positive pregnant women can help in assessing their risk for complications and tailoring appropriate management strategies.

HIV and Pregnancy

HIV infection introduces a range of complexities to pregnancy, impacting both maternal and fetal health [29]. Women living with HIV are at an increased risk for a variety of pregnancy-related complications, including preterm birth, low birth weight, and maternal morbidities such as preeclampsia and gestational diabetes. The presence of HIV can exacerbate these risks due to the virus's effects on the immune system, which can lead to heightened vulnerability to infections and other health issues. Additionally, the increased inflammation and immune activation associated with HIV can further complicate the pregnancy. Antiretroviral therapy (ART) is crucial in managing HIV and preventing mother-to-child transmission of the virus [30]. ART has significantly improved outcomes for pregnant women with HIV and their infants by reducing viral loads to undetectable levels. However, ART can also influence various hematological parameters, including Red Cell Distribution Width (RDW). The interaction between ART and RDW is complex, as some ART regimens may impact red blood cell production and turnover, potentially altering RDW levels. Monitoring RDW in the context of ART can help assess the impact of treatment on maternal health and guide necessary adjustments. Pregnant women with HIV face a higher risk of several specific complications. For instance, the risk of preeclampsia—a condition characterized by high blood pressure and organ damage—is elevated in HIV-positive women. Additionally, there is an increased likelihood of preterm labor and delivery, which can result in adverse outcomes for the infant, including low birth weight and developmental issues. HIV-related immune suppression can also lead to an increased risk of opportunistic infections, which may further complicate the pregnancy and necessitate careful management.

The management of maternal health in HIV-positive pregnant women involves addressing both the effects of HIV and the implications of ART [31]. Regular monitoring of HIV-related health markers, such as CD4 cell counts and viral load, is essential for optimizing treatment and minimizing complications. Additionally, screening for and managing co-existing conditions, such as anemia and nutritional deficiencies, is important for maintaining overall health and well-being. RDW, as a marker of red blood cell variability, can provide additional insights into maternal health and the potential impact of HIV and ART on red blood cell production. Preventing vertical transmission of HIV is a primary goal during pregnancy [32]. Effective ART can significantly reduce the risk of transmitting HIV from mother to child. Regular monitoring and management are required to ensure that viral loads remain undetectable and to prevent transmission during childbirth. Additionally, monitoring the fetus for signs of growth restriction or other complications related to maternal HIV can help in managing the health of the infant and planning appropriate interventions.

RDW Fluctuations in HIV-Affected Pregnant Women

During pregnancy, RDW levels can fluctuate due to physiological changes such as hemodilution, increased red blood cell production, and alterations in nutritional status. Elevated RDW may reflect underlying conditions such as anemia, inflammation, or nutritional deficiencies, which are pertinent in the context of pregnancy. HIV infection can significantly affect RDW levels due to the virus's impact on red blood cell production and turnover [33]. Chronic inflammation and immune system dysregulation associated with HIV can lead to alterations in hematological parameters, including RDW. HIV can also contribute to anemia through various mechanisms, such as the direct effects of the virus on bone marrow, nutrient deficiencies, and the impact of co-infections or opportunistic diseases. As a result, RDW levels in HIV-positive pregnant women may differ from those in HIV-negative pregnant women, potentially reflecting both the effects of the infection and the treatment.

Antiretroviral therapy (ART), essential for managing HIV and reducing the risk of mother-to-child transmission, can also influence RDW levels [34]. Different ART regimens have varying effects on

hematological parameters. Some ART drugs can impact red blood cell production or contribute to conditions like anemia, which in turn can affect RDW. For instance, certain medications may lead to vitamin deficiencies or bone marrow suppression, influencing RDW fluctuations. Monitoring RDW in the context of ART helps assess how treatment impacts maternal hematological health and informs potential adjustments to therapy. Fluctuations in RDW levels during pregnancy in HIV-positive women may serve as an early indicator of potential complications [35]. Elevated RDW can signal conditions such as anemia, inflammation, or other underlying health issues. For instance, increased RDW levels may indicate a risk for preeclampsia or gestational diabetes, both of which are more prevalent in HIV-positive pregnancies. By regularly monitoring RDW, healthcare providers can identify potential problems early and implement appropriate interventions to manage risks and improve pregnancy outcomes.

CONCLUSION

Red Cell Distribution Width (RDW) is a valuable hematological parameter that offers insights into red blood cell variability and overall health. In the context of pregnancy, particularly among women living with HIV, RDW fluctuations can provide important information about maternal and fetal well-being. Elevated RDW levels during pregnancy may signal underlying conditions such as anemia, inflammation, or nutritional deficiencies, and are associated with an increased risk of complications like preeclampsia, gestational diabetes, and preterm birth. HIV introduces additional complexities to pregnancy, influencing RDW through the effects of chronic inflammation, immune system dysregulation, and the impact of antiretroviral therapy (ART). While ART is crucial for managing HIV and preventing mother-to-child transmission, it can also affect hematological parameters, including RDW. Understanding how HIV and ART impact RDW levels is essential for optimizing maternal health and managing potential complications.

REFERENCES

1. Chilaka, V. N., & Konje, J. C. (2021). HIV in pregnancy–An update. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, *256*, 484-491.
2. Obeagu, E. I., Anyiam, A. F., & Obeagu, G. U. (2024). Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, *2*(1), 16-30.
3. Okamgba, O. C., Nwosu, D. C., Nwobodo, E. I., Agu, G. C., Ozims, S. J., Obeagu, E. I., ... & Ifeanyichukwu, M. O. (2017). Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*, *5*(4), 206.
4. Obeagu, E. I., & Obeagu, G. U. (2024). Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*, *2*(1), 37-50.
5. Obeagu, E. I., & Obeagu, G. U. (2024). Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*, *10*(1), 11-24.
6. Agreen, F. C., & Obeagu, E. I. (2023). Anaemia among pregnant women: A review of African pregnant teenagers. *Journal of Public Health and Nutrition*, *6*(1), 138.
7. Figueroa-Mujica, R., Ccahuantico, L. A., Ccorahua-Rios, M. S., Sanchez-Huaman, J. J., Vásquez-Velasquez, C., Ponce-Huarancca, J. M., ... & Gonzales, G. F. (2022). A critical analysis of the automated hematology assessment in pregnant women at low and at high altitude: association between red blood cells, platelet parameters, and iron status. *Life*, *12*(5), 727.
8. Yılmaz, Z. V., Yılmaz, E., İçer, B., & Küçüközkan, T. (2017). Association of complete blood count parameters with gestational diabetes mellitus. *Gynecology obstetrics & reproductive medicine*, *23*(2), 65-69.
9. Obeagu, E. I., Obeagu, G. U., Chukwueze, C. M., Ikpenwa, J. N., & Ramos, G. F. (2022). Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. *Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035*, *2*(2), 1-9.
10. Obeagu, E. I., Obeagu, G. U., Hauwa, B. A., & Umar, A. I. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: http://www. journalijiar. com*, *12*(01).
11. Obeagu, E. I., Abdirahman, B. F., Bunu, U. O., & Obeagu, G. U. (2023). Obsterics characteristics that effect the newborn outcomes. *Int. J. Adv. Res. Biol. Sci*, *10*(3), 134-143.
12. Obeagu, E. I., & Obeagu, G. U. (2024). Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*, *2*(1), 14-32.
13. Obeagu, E. I., & Obeagu, G. U. (2024). P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*, *2*(1), 17-41.
14. Duguma, N., Tesfaye Kiya, G., Adissu Maleko, W., & Bimerew, L. G. (2021). Hematological parameters abnormalities and associated factors in HIV-positive adults before and after highly active antiretroviral treatment in Goba Referral Hospital, southeast Ethiopia: a cross-sectional study. *SAGE open medicine*, *9*, 20503121211020175.
15. Aaron, U. U., Okonko, I. O., & Frank-Peterside, N. (2021). Haematological Indices of HIV-1 Infected Subjects on Antiretroviral Therapy from Selected Tertiary Hospitals in Port Harcourt, Nigeria. *Asian Hematology Research Journal*, *5*(3), 12-19.

16. Tinarwo, P., Zewotir, T., Yende-Zuma, N., Garrett, N. J., & North, D. (2019). An evaluation to determine the strongest CD4 count covariates during HIV disease progression in women in South Africa. *Infectious diseases and therapy*, *8*, 269-284.
17. Caporal, F. A., & Comar, S. R. (2013). Evaluation of RDW-CV, RDW-SD, and MATH-1SD for the detection of erythrocyte anisocytosis observed by optical microscopy. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, *49*, 324-331.
18. Constantino, B. T. (2013). Red cell distribution width, revisited. *Laboratory Medicine*, *44*(2), e2-e9.
19. Poz, D., De Falco, E., Pisano, C., Madonna, R., Ferdinandy, P., & Balistreri, C. R. (2019). Diagnostic and prognostic relevance of red blood cell distribution width for vascular aging and cardiovascular diseases. *Rejuvenation Research*, *22*(2), 146-162.
20. Figueroa-Mujica, R., Ccahuantico, L. A., Ccorahua-Rios, M. S., Sanchez-Huaman, J. J., Vásquez-Velasquez, C., Ponce-Huarancca, J. M., ... & Gonzales, G. F. (2022). A critical analysis of the automated hematology assessment in pregnant women at low and at high altitude: association between red blood cells, platelet parameters, and iron status. *Life*, *12*(5), 727.
21. Obeagu, E. I., & Obeagu, G. U. (2024). The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*, *11*(2), 30-40.
22. Obeagu, E. I., Anyiam, A. F., & Obeagu, G. U. (2024). Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*, *2*(1), 51-64.
23. Obeagu, E. I., & Obeagu, G. U. (2024). Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*, *2*(1), 1-16.
24. Kyeong, K. S., Shim, J. Y., Lee, M. Y., Lee, K. A., Won, H. S., Lee, P. R., & Kim, A. (2012). Perinatal/Maternal-Fetal Medicine. *Parameters*, *1*, 004.
25. Garofoli, F., Ciardelli, L., Mazzucchelli, I., Borghesi, A., Angelini, M., Bollani, L., ... & Stronati, M. (2014). The red cell distribution width (RDW): value and role in preterm, IUGR (intrauterine growth restricted), full-term infants. *Hematology*, *19*(6), 365-369.
26. Malandrino, N., Wu, W. C., Taveira, T. H., Whitlatch, H. B., & Smith, R. J. (2012). Association between red blood cell distribution width and macrovascular and microvascular complications in diabetes. *Diabetologia*, *55*, 226-235.
27. Salvagno, G. L., Sanchis-Gomar, F., Picanza, A., & Lippi, G. (2015). Red blood cell distribution width: a simple parameter with multiple clinical applications. *Critical reviews in clinical laboratory sciences*, *52*(2), 86-105.
28. Patxot, M., Stojanov, M., Ojavee, S. E., Gobert, R. P., Kutalik, Z., Gavillet, M., ... & Robinson, M. R. (2022). Haematological changes from conception to childbirth: An indicator of major pregnancy complications. *European Journal of Haematology*, *109*(5), 566-575.
29. De Ruiter, A., Taylor, G. P., Clayden, P., Dhar, J., Gandhi, K., Gilleece, Y., ... & Wilkins, E. (2012). Guidelines for the management of HIV infection in pregnant women 2012. *HIV med*, *13*(Suppl 2), 87-157.
30. Dong, Y., Guo, W., Gui, X., Liu, Y., Yan, Y., Feng, L., & Liang, K. (2020). Preventing mother to child transmission of HIV: lessons learned from China. *BMC Infectious Diseases*, *20*, 1-10.
31. Sturt, A. S., Dokubo, E. K., Sint, T. T., & Cochrane HIV/AIDS Group. (1996). Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. *Cochrane Database of Systematic Reviews*, *2010*(6).
32. Cardenas, M. C., Farnan, S., Hamel, B. L., Mejia Plazas, M. C., Sintim-Aboagye, E., Littlefield, D. R., ... & Chakraborty, R. (2023). Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far. *Viruses*, *15*(4), 849.
33. Mahmood, N. A., Mathew, J., Kang, B., DeBari, V. A., & Khan, M. A. (2014). Broadening of the red blood cell distribution width is associated with increased severity of illness in patients with sepsis. *International journal of critical illness and injury science*, *4*(4), 278-282.
34. Ziske, J., Kunz, A., Sewangi, J., Lau, I., Dugange, F., Hauser, A., ... & Theuring, S. (2013). Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child-transmission of HIV in Tanzania. *PloS one*, *8*(2), e55633.
35. Ositadinma, I. M., Ikponmwosa, O. S., & Okechukwu, O. C. (2015). Haemorheology and Red Cell indices in HIV Positive Individuals on Antiretroviral Therapy in Delta State, Nigeria. *International Journal of Current Research and Review*, *7*(12), 24.